Arcus Biosciences to Host Conference Call to Discuss Fourth-Quarter and Full-Year 2023 Financial Results and Pipeline Updates
07 Fevereiro 2024 - 7:00PM
Business Wire
Arcus Biosciences (NYSE:RCUS), a clinical-stage, global
biopharmaceutical company focused on developing differentiated
molecules and combination therapies for people with cancer,
announced that its management team will host a conference call and
webcast on Wednesday, February 21, 2024 at 2:00 PM PT / 5:00 PM ET
to discuss pipeline updates and details of the Company’s financial
results for the quarter and year ended December 31st, 2023.
Investors interested in listening to the conference call may do
so by dialing (404) 975-4839 (local) or (833) 470-1428 (toll-free),
using Access Code: 235272. To access the live webcast and
accompanying slide presentation, please visit the “Investors &
Media” section of the Arcus Biosciences website at
www.arcusbio.com. A replay of the webcast will be available
following the live event.
About Arcus Biosciences
Arcus Biosciences is a clinical-stage, global biopharmaceutical
company developing differentiated molecules and combination
medicines for people with cancer. In partnership with industry
collaborators, patients and physicians around the world, Arcus is
expediting the development of first- or best-in-class medicines
against well-characterized biological targets and pathways and
studying novel, biology-driven combinations that have the potential
to help people with cancer live longer. Founded in 2015, the
company has expedited the development of multiple investigational
medicines into clinical studies, including new combination
approaches that target TIGIT, PD-1, the adenosine axis (CD73 and
dual A2a/A2b receptor), HIF-2a, CD39 and AXL. For more information
about Arcus Biosciences’ clinical and preclinical programs, please
visit www.arcusbio.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240207640939/en/
Media Inquiries Holli Kolkey VP of Corporate
Communications (650) 922-1269 hkolkey@arcusbio.com
Investor Inquiries Pia Eaves Head of Investor Relations
& Strategy (617) 459-2006 peaves@arcusbio.com
Arcus Biosciences (NYSE:RCUS)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
Arcus Biosciences (NYSE:RCUS)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024
